Translate
Astellas Pharma Inc.
About
2,367.50JPY-9.50 -0.40%
Closed • Updated at 10:28 GMT+00:00Market Cap$27.12B
P/E Ratio14.59
Volume4.54M
Beta1.02
RSI45.01
Gross Margin74.55%
Astellas Pharma Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
Yesterday
Japan Regenerative Medicine Market Trends and Forecasts to 2035 Featuring Astellas Pharma, Fujifilm, JCR Pharmaceuticals, Sumitomo Pharma, Takeda, and Terumo
May 12 2026
IZERVAY® (avacincaptad pegol intravitreal solution) Demonstrated Increased Probability of Maintaining Driving Eligibility in Geographic Atrophy Patients
Apr 30 2026
Astellas to Highlight New Findings for Geographic Atrophy at ARVO 2026 Annual Meeting
Apr 20 2026
U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Apr 8 2026
Dyno Therapeutics Announces Capsid License Exercised by Astellas for Skeletal Muscle-Targeted Gene Delivery, Validating AI-Powered Technology for Biological Sequence Design
Recent Videos
Humans at Frontier | アステラス製薬株式会社
May 07, 2026
【5/5LIVE】アステラス製薬下落バンドウォーク上昇サインくる？ #日経平均株価 #投資
May 06, 2026
高配当TOP製薬会社の武田製薬VSアステラス製薬は買い？
May 02, 2026
Humans at Frontier｜アステラス製薬株式会社
May 01, 2026